EN ▾
SNAPE REP RT Front page →
ConfirmedMedicine19 Nov, 03:57 UTC

FDA upholds rejection of Echo IQ's EchoSolv HF heart-failure AI after appeal

The FDA kept its “not substantially equivalent” finding; Echo IQ shares fell 42% and the company is weighing a new 510(k), while its EchoSolv AS tool stays cleared.

Read at Grafa Share

Sources

More on Medicine
More from Snape ReportFront page →